GÉTICA 2021

23 [ F I T C á n c e r - 7 ] administration. We show that intratumor release, transient IL-12 engineering and re- peated administrations jointly constitute a safe, feasible, and powerful cancer immuno- therapy strategy. cell for ACT. In this line, we developed an ex- perimental strategy to enhance the efficacy of adoptive T-cell therapy by means of tran- sient gene engineering with mRNA encoding IL-12 and CD137L, as well as by intratumor NOTAS